Lord, Abbett & Co. LLC Arcus Biosciences, Inc. Transaction History

Lord, Abbett & Co. LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$9.74 - $14.5 $2.96 Million - $4.41 Million	-304,343 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.95 $97,691 - $134,236	8,979 Added 3.04%	304,343 $4.24 Million
Q2 2018 Aug 14, 2018	SELL	$12.24 - $17.05 $65,239 - $90,876	-5,330 Reduced 1.77%	295,364 $3.62 Million
Q1 2018 May 15, 2018	BUY	$15.44 - $17.71 $4.64 Million - $5.33 Million	300,694 New	300,694 $4.64 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.